[
    [
        {
            "time": "",
            "original_text": "华大基因净利润降三成 新冠检测试剂“降价”后如何打造增长曲线 盈利能力下降",
            "features": {
                "keywords": [
                    "华大基因",
                    "净利润",
                    "新冠检测试剂",
                    "降价",
                    "增长曲线",
                    "盈利能力下降"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医疗",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "华大基因净利润降三成 新冠检测试剂“降价”后如何打造增长曲线 盈利能力下降",
                "Correlation": 10,
                "Sentiment": 3,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "华大基因上半年净利同比降超三成：收入较去年疫情突发时略降 盈利能力下降",
            "features": {
                "keywords": [
                    "华大基因",
                    "上半年",
                    "净利",
                    "同比下降",
                    "疫情",
                    "收入下降",
                    "盈利能力下降"
                ],
                "sentiment_score": -0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医疗",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "华大基因上半年净利同比降超三成：收入较去年疫情突发时略降 盈利能力下降",
                "Correlation": 10,
                "Sentiment": 3,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "华大基因上半年净利润逾10亿元 打造“平疫结合”双业务模式",
            "features": {
                "keywords": [
                    "华大基因",
                    "上半年",
                    "净利润",
                    "10亿元",
                    "平疫结合",
                    "双业务模式"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医疗",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "华大基因上半年净利润逾10亿元 打造“平疫结合”双业务模式",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        }
    ]
]